• Full Prescribing Information
  • Patient Information
  • Instructions for Use
  • Medical Information

    • Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

    Click here to learn how we are responding.

    PFIZER IS BUILDING ONTO THE CLINICAL EXPERIENCE OF PEGFILGRASTIM

    ​​​​​​NYVEPRIA is an FDA-approved biosimilar to Neulasta® (pegfilgrastim)1*

    NYVEPRIA offers the potential to help address treatment costs and was approved by the FDA based on the totality of evidence supporting high similarity to Neulasta1-3† 

    Potential cost savings with NYVEPRIA

    Wholesale aquisition cost (WAC) represents a 37% discount vs Neulasta per 6mg prefilled syringe 2‡​​​​​​​§

    Card CTA

    ** This is an optional area where footnotes can live.

       *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1

        †NYVEPRIA does not have a designation of interchangeability with Neulasta.

        ‡WAC is a manufacturer's undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations.

        §As of May 2021.

    Approved for the eligible indication of Neulasta1

    See full indication

    NYVEPRIA PD/PK data supports no clinically meaningful differences in efficacy vs Neulasta2

    Studies in support of biosimilarity in healthy volunteers

    Review clinical data

    NYVEPRIA had a comparable safety profile vs Neulasta across adverse event categories2

    Studies in support of biosimilarity in healthy volunteers

    Review safety data

    Dosing and administration identical to that of Neulasta1,4

    Review dosing information

    A program designed to help identify financial support options for eligible patients and to connect patients to resources for emotional support

    Learn more
    Contraindications
    • NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
    • Reactions have included anaphylaxis
    Warnings and Precautions
    Splenic Rupture
    • Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
    • Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA
    Acute Respiratory Distress Syndrome (ARDS)
    • ARDS can occur in patients receiving pegfilgrastim products
    • Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
    • Discontinue NYVEPRIA in patients with ARDS
    Serious Allergic Reactions
    • Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
    • The majority of reported events occurred upon initial exposure
    • Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti‐allergic treatment
    • Permanently discontinue NYVEPRIA in patients with serious allergic reactions
    • Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
    Use in Patients with Sickle Cell Disorders
    • Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
    • Discontinue NYVEPRIA if sickle cell crisis occurs
    Glomerulonephritis
    • Glomerulonephritis has occurred in patients receiving pegfilgrastim products
    • The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
    • Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
    • If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA
    Leukocytosis
    • White blood cell counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim products
    • Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended
    Thrombocytopenia
    • Thrombocytopenia has been reported in patients receiving pegfilgrastim products
    • Monitor platelet counts
    Capillary Leak Syndrome (CLS)
    • CLS has been reported after granulocyte-colony stimulating factor (G‐CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
    • Episodes vary in frequency and severity and may be life‐threatening if treatment is delayed
    • Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care
    Potential for Tumor Growth Stimulatory Effects on Malignant Cells
    • The G-CSF receptor through which pegfilgrastim and filgrastim products act has been found on tumor cell lines
    • The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded
    Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer
    • MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer
    • Monitor patients for signs and symptoms of MDS/AML in these settings
    Aortitis
    • Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
    • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and white blood cell count)
    • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NYVEPRIA if aortitis is suspected
    Nuclear Imaging
    • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results
    Most Common Adverse Reactions
    • Bone pain
    • Pain in extremity

    NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

    Limitations of Use

    NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

    Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.

    Indication

    NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

     
    Limitations of Use
     

    NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

    Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.